|Dr. Ulrik B. Nielsen Ph.D.||Co-Founder & Director||45k||982k||45|
|Dr. Richard Peters M.D., Ph.D.||Pres, CEO & Director||N/A||N/A||54|
|Dr. Anthony J. Sinskey Sc.D.||Co-Founder and Scientific Advisor||N/A||N/A||77|
|Dr. Gavin MacBeath Ph.D.||Founder||N/A||N/A||N/A|
|Mr. John L. Green||Principal Accounting Officer & Controller||N/A||N/A||37|
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. Its therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors. Further, it is developing preclinical product candidates for solid tumor indications. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 5; Compensation: 9.